{"filings":[{"id":1940929,"accession_number":"0001193125-26-323753","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2026-07-29T20:15:15+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q2 revenue $71.6M (+22% YoY); MRD up 33%; raises FY MRD guidance; CSO transitions to consultant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $71.6M (+22% YoY); MRD revenue $66.2M (+33% YoY); clonoSEQ volume 36,111 (+43% YoY).","Net loss $39.9M (incl. $23.7M loss on OrbiMed settlement); adjusted EBITDA loss improved to $0.7M from $7.2M.","Completed $345M zero-coupon convertible notes offering; repaid OrbiMed Purchase Agreement; cash $371.7M.","Raised FY 2026 MRD revenue guidance to $268M-$278M (from $260M-$270M); total opex guidance narrowed to $350M-$355M.","CSO and co-founder Harlan Robins transitions to strategic consultant role; no disagreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1194836,"accession_number":"0001193125-26-277516","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2026-06-22T20:07:07+00:00","items":["1.01","1.02","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Adaptive Biotech prices $345M 0% convertible notes; repays OrbiMed, repurchases $25M stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $345M 0% convertible notes due 2031; net proceeds ~$334.5M after discounts and expenses.","Used $25.6M for capped call transactions and $25M to repurchase 1.45M shares of common stock.","Used $156.9M to repay OrbiMed Purchase Agreement (original $124.4M, payoff at 156% cap).","Conversion price $24.11 (40% premium over $17.22 close); cap price $34.44 (100% premium).","Remaining net proceeds for general corporate purposes and opportunistic MRD initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1056877,"accession_number":"0001193125-26-271117","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2026-06-15T20:15:51+00:00","items":["8.01","9.01"],"status":"ready","headline":"Adaptive Biotechnologies proposes $250M notes offering, plans MRD/Immune Medicine separation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Intends to issue $250M convertible senior notes due 2031 (plus $37.5M option) to qualified institutional buyers.","Proceeds to repay OrbiMed Purchase Agreement (~$156.9M), repurchase up to $25M stock, and fund capped calls.","Plans to separate MRD and Immune Medicine businesses; expects to identify preferred path by year-end 2026.","MRD revenue grew to $212M in 2025 (from $103M in 2023), with $15M adjusted EBITDA.","Immune Medicine has over 6M functional TCR-antigen pairs and data on 10,000+ patients; evaluating alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":946414,"accession_number":"0001193125-26-263844","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2026-06-09T20:30:16+00:00","items":["5.07"],"status":"ready","headline":"Adaptive Biotechnologies annual meeting results: directors elected, say-on-pay approved, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Robert Hershberg elected Class I director with 71.81% of votes cast; 13.6M broker non-votes.","Katey Owen elected Class I director with 97.72% of votes cast.","Advisory vote on 2025 named executive officer compensation passed with 96.55% approval.","Ratification of Ernst & Young as auditor for FY 2026 approved with 99.50% of votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93089,"accession_number":"0001193125-26-206455","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q1 revenue $70.9M, up 35% YoY; MRD revenue up 53%; raises FY2026 MRD guidance to $260-270M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $70.9M (+35% YoY); MRD revenue $67.1M (+53% YoY); clonoSEQ test volume 32,595 (+41%).","Net loss narrowed to $20.0M from $29.8M; adj. EBITDA loss $2.5M improved from $12.7M loss.","Raised FY2026 MRD revenue guidance to $260-270M (from $255-265M), implying 22-27% annual growth.","Recognized $9.0M in MRD pharma regulatory milestone revenue, first U.S. primary endpoint milestone.","Immune Medicine revenue $3.8M (-57% YoY); cash & equivalents $237.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":70874000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104419,"accession_number":"0001193125-26-039409","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q4 rev $71.7M (+51% YoY); MRD profitable; FY2026 MRD rev guide $255-265M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $71.7M (+51% YoY); FY revenue $277.0M (+55% YoY); net loss narrowed to $13.6M and $59.5M.","MRD segment achieved positive Adjusted EBITDA and cash flow; MRD revenue Q4 $61.9M (+54%), FY $212.3M (+46%).","clonoSEQ test volume Q4 30,038 (+43% YoY); FY 105,587 (+39% YoY); expanded Medicare coverage in mantle cell lymphoma.","Signed two non-exclusive immune receptor data licensing agreements with Pfizer.","FY2026 guidance: MRD revenue $255-265M; total OpEx $350-360M; management expects company-wide profitability in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":276976000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104418,"accession_number":"0001193125-26-009840","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Adaptive Biotechnologies reports preliminary Q4/FY2025 revenue growth of 51%/55% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue FY2025 ~$277M (+55% YoY); Q4 ~$72M (+51% YoY).","MRD revenue FY2025 ~$212M (+46% YoY); excluding milestone revenue grew 45%.","clonoSEQ test volume FY2025 ~105,600 tests (+39% YoY); Q4 ~30,000 tests (+43% YoY).","Cash, cash equivalents and marketable securities ~$227M as of Dec 31, 2025.","Company expects full FY2025 net loss to decrease vs 2024; complete results due Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":276976000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120710,"accession_number":"0001193125-25-335921","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Adaptive Biotechnologies subsidiary Digital Biotechnologies closes Series A up to $15M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Digital Biotechnologies, 70%-owned subsidiary, held initial closing of Series A Preferred Stock financing.","Anticipated total proceeds of up to $15 million from the Series A round.","Upon completion, Adaptive expects to retain nearly 50% ownership and continue consolidating Digital's results.","Digital Biotechnologies is an early-stage company with no revenues and limited activities to date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120709,"accession_number":"0001193125-25-266974","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q3 revenue $94M (+102% YoY); MRD profitable, guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $94.0M (up 102% YoY) includes $33.7M from full amortization of Genentech payment.","MRD revenue $56.8M (+52% YoY); MRD achieved profitability and cash flow positivity with Adj. EBITDA $7.0M.","clonoSEQ test volume 27,111 (+38% YoY); NCCN guidelines updated for CLL MRD-guided treatment duration.","Net income $9.5M vs $32.1M loss in Q3 2024; Adj. EBITDA $28.0M vs $14.3M loss.","FY2025 MRD revenue guidance raised to $202-207M; total operating spend and cash burn guidance reduced."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":205295000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137302,"accession_number":"0001193125-25-182222","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Adaptive and Genentech terminate cell therapy collaboration; $33.7M non-cash revenue in H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Strategic Collaboration and License Agreement with Genentech terminated Aug 13, 2025; effective Feb 9, 2026.","Adaptive expects $33.7M non-cash revenue in H2 2025 from remaining amortization of cash consideration.","Company released from exclusivity obligations in oncology cell therapies.","Ongoing Immune Medicine programs: digital TCR-antigen models, T-cell depletion in autoimmunity, FY2025 cash burn target $25-30M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137301,"accession_number":"0000950170-25-103058","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Q2 MRD revenue up 42%, achieves MRD profitability; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $58.9M (+36% YoY); MRD revenue $49.9M (+42% YoY); MRD Adjusted EBITDA positive $1.9M.","clonoSEQ volume 25,321 (+37% YoY); Immune Medicine revenue $8.9M (+13% YoY).","Net loss $25.6M ($46.2M in Q2 2024); Adjusted EBITDA loss $7.2M vs $21.4M prior year.","FY 2025 MRD revenue guidance raised to $190-200M (from $180-190M); cash burn guidance lowered to $45-55M.","Cash $222M; launched clonoSEQ integration into Flatiron OncoEMR; recognized $5.5M pharma milestone revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":111322000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154616,"accession_number":"0001193125-25-140017","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Adaptive Biotechnologies shareholders elect Chad Robins and approve say-on-pay, auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Chad Robins elected Class III director with 80.95% of votes cast; 12.8M broker non-votes.","Say-on-pay advisory proposal passed with 98.46% support; 1.23% against.","Ratification of Ernst & Young as 2025 auditor approved with 99.91% of votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154615,"accession_number":"0000950170-25-061851","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q1 revenue up 25% to $52.4M; raises MRD guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $52.4M (+25% YoY); MRD revenue $43.7M (+34%); clonoSEQ volume up 36% to 23,117 tests.","Net loss narrowed to $29.8M from $47.5M; adjusted EBITDA loss $12.7M from $28.2M.","Raises FY 2025 MRD revenue guidance to $180-190M (from $175-185M); lowers cash burn target to $50-60M.","Expanded Medicare coverage for clonoSEQ in mantle cell lymphoma recurrence monitoring.","Cash, equivalents, and marketable securities $232.8M at March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":52443000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173144,"accession_number":"0000950170-25-017915","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotech Q4 revenue $47.5M; MRD revenue up 31% YoY; FY2025 MRD guidance $175-185M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $47.5M (+4% YoY); full year $179.0M (+5%). MRD revenue $40.1M (+31% Q4, +42% FY).","clonoSEQ test volume Q4 20,945 tests (+34% YoY); full year 76,105 tests (+35%).","Net loss Q4 $33.7M vs $69.5M a year ago; FY net loss $159.6M vs $225.3M. Adjusted EBITDA loss Q4 $16.4M vs $24.7M.","FY2025 guidance: MRD revenue $175-185M; total operating expenses $340-350M; cash burn $60-70M.","FDA ODAC unanimously voted to support MRD as primary endpoint for accelerated approval in multiple myeloma."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":178957000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190169,"accession_number":"0000950170-24-123369","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q3 revenue $46.4M (+22%); MRD revenue up 52%; net loss narrows to $32.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $46.4M (+22% YoY); MRD revenue $37.5M (+52%); Immune Medicine $9.0M (-32%).","Net loss $32.1M vs $50.3M YoY; Adjusted EBITDA loss $14.3M vs $29.8M.","clonoSEQ test volume 19,600 (+30%); Medicare gapfill rate raised 17% to $2,007/test.","MRD revenue guidance raised to $143-145M (prev. $140-145M); op. expense guidance cut to $335-340M.","Cash, cash equivalents and marketable securities $267.2M; interest expense on revenue interest purchase $2.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":131498000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206677,"accession_number":"0000950170-24-089301","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q2 MRD revenue up 36% YoY; updates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q2 revenue $43.2M (-12% YoY); MRD revenue $35.3M (+36%), Immune Medicine $7.9M (-66%).","Net loss $46.2M vs $47.8M YoY; Adjusted EBITDA loss $21.4M vs $24.8M.","clonoSEQ test volume 18,520 (+36% YoY); recognized $3.0M MRD regulatory milestone.","FY 2024 MRD revenue guidance raised to $140-145M (from $135-140M); total OPEX guidance lowered to $340-350M.","Cash and securities $291.9M as of June 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":85063000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223873,"accession_number":"0000950170-24-071913","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Shareholders elect directors with majority support; Nasdaq confirms audit committee compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Peter Neupert elected with 69.15% for (30.85% withhold); Michelle Griffin with 82.93% for.","Advisory vote on 2023 executive compensation passed with 86% support.","Ratification of Ernst & Young as independent auditor for FY2024 passed with 99.6% approval.","Nasdaq confirmed compliance with Listing Rule 5605(c)(2) after Peter Neupert joined audit committee in July 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223872,"accession_number":"0000950170-24-054513","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q1 2024: MRD revenue up 52% to $32.6M; net loss narrows to $47.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $41.9M (+11% YoY); MRD $32.6M (+52%), Immune Medicine $9.2M (-43%).","clonoSEQ test volume rose 41% to 17,040; net loss improved to $47.5M from $57.7M.","Cash $308.9M; FY2024 MRD revenue guidance raised to $135-140M, opex lowered to $350-360M.","FDA ODAC unanimously supported MRD as primary endpoint for accelerated approval in multiple myeloma.","Strategic move: MRD and Immune Medicine to report separately; antibody discovery launched for MS and type 1 diabetes."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":41873000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223871,"accession_number":"0001193125-24-090983","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies appoints Kyle Piskel as CFO effective April 8, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kyle Piskel promoted from Principal Accounting Officer to CFO; reports to CEO Chad Robins.","Base salary set at $380,000 per year; target bonus of 40% of eligible earnings.","Receives RSU grant of 31,260 shares (4-year vesting) and PSU grant of 75,000 shares (3-year performance period).","Also entitled to annual equity refresh of 43,740 RSUs, bringing 2024 total equity grants to 150,000 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223870,"accession_number":"0000950170-24-042291","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotech Q1 prelim rev ~$41-43M (+12% YoY); CFO Peterson departs, Piskel named","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary total Q1 2024 revenue of ~$41-43M, up ~12% vs Q1 2023.","MRD revenue ~$31-32M, up ~47% YoY; Immune Medicine revenue implied by difference.","Strategic review concludes: run MRD and Immune Medicine internally with separate resources and segment reporting.","CFO Tycho Peterson departs; Kyle Piskel (Principal Accounting Officer, 8-yr tenure) appointed full-time CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223869,"accession_number":"0001193125-24-084748","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Tycho Peterson resigns; Kyle Piskel named CFO effective April 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tycho Peterson resigned as CFO effective April 5, 2024; resignation voluntary with no disagreement.","Kyle Piskel, current Principal Accounting Officer and 8-year veteran, appointed CFO starting April 8, 2024.","No other leadership changes or compensatory arrangements disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243257,"accession_number":"0000950170-24-015230","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotech Q4 revenue down 17% to $45.8M; net loss widens to $69.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2023 revenue $170.3M (-8% YoY); MRD revenue $102.7M (+18%) offset by IM decline.","clonoSEQ test volume up 53% YoY to 56,496 tests delivered in 2023.","Net loss $225.3M in 2023 vs $200.4M in 2022; includes $25.4M lease impairment charge.","Adjusted EBITDA loss $116.4M in 2023 vs $121.6M loss in 2022.","2024 MRD revenue guidance $130-140M; total OpEx guided to $360-370M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":170276000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260657,"accession_number":"0000950170-23-062077","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q3 revenue down 21% to $37.9M; launches strategic review with Goldman Sachs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2023 revenue $37.9M, down 21% YoY; net loss $50.3M vs $45.3M; Adjusted EBITDA loss $29.8M vs $25.9M.","MRD revenue $24.7M (+24% YoY); Immune Medicine revenue $13.3M (-52% YoY); clonoSEQ test volume +56% to 15,072.","Strategic review of MRD and Immune Medicine businesses underway with Goldman Sachs to maximize shareholder value.","Full-year 2023 guidance: MRD revenue $100-105M; total operating expenses ~$375M; Immune Medicine revenue guidance removed.","Discovered novel multiple sclerosis target, validating autoimmune target discovery approach."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":124492000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277940,"accession_number":"0001193125-23-227739","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Kevin Conroy resigns from Adaptive Biotechnologies board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Conroy voluntarily resigned from the Board effective September 1, 2023.","Resignation not due to any disagreement with Company on operations, policies or practices.","Company expressed gratitude for Mr. Conroy's years of service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277939,"accession_number":"0000950170-23-037192","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Adaptive Biotech Q2 revenue up 12% to $48.9M; net loss narrows; MRD chief exits","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $48.9M (+12% YoY); MRD revenue $25.9M (+22%); Immune Medicine $23.0M (+3%).","clonoSEQ test volume +52% to 13,665 tests delivered.","Net loss $47.8M vs $52.1M YoY; adjusted EBITDA loss $24.8M vs $33.1M.","Full-year 2023 revenue guidance reiterated at $205-215M; operating expenses expected below 2022's $385.5M.","Nitin Sood, Chief Commercial Officer of MRD, resigns effective Aug 15; Susan Bobulsky assumes additional responsibilities, reports to CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":86573000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277938,"accession_number":"0001193125-23-181293","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Adaptive Biotechnologies receives Nasdaq notice for Audit Committee non-compliance after director resignation","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On June 13, 2023, board member Leslie Trigg resigned, reducing Audit Committee to two members.","Nasdaq rule 5605(c)(2)(A) requires at least three members on Audit Committee.","Company received non-compliance notice on June 26, 2023, with a cure period to regain compliance.","Company is evaluating board committee composition and intends to cure within the applicable period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295966,"accession_number":"0000950170-23-027702","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Director Robert Hershberg fails to win majority support at AGM; Leslie Trigg resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Hershberg received 44.02% for, 55.97% withhold/abstain in Class 1 director election; Katey Owen elected with 76.66%.","Leslie Trigg voluntarily resigned from board effective June 9, 2023; no disagreement with company.","Advisory vote on 2022 NEO compensation passed with 82.68% support.","Ernst & Young ratified as independent auditor for FY2023 with 99.72% shareholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295965,"accession_number":"0001193125-23-138915","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA accepts IND for first neoantigen-directed T-cell therapy from Adaptive-Genentech collaboration","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted IND for TCR-based T-cell therapy candidate; first from collaboration to enter clinical development.","Therapy targets neoantigens identified via Adaptive's TCR discovery platform.","Genentech responsible for clinical, regulatory, and commercialization efforts.","Adaptive reaffirms FY2023 revenue guidance of $205-215 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295964,"accession_number":"0000950170-23-017194","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q1 net loss $57.7M; clonoSEQ volume up 57% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $37.6M (-3% YoY); MRD $21.4M (+20%); Immune Medicine $16.2M (-22% due to Genentech amortization decline).","clonoSEQ test volume 12,079 (+57% YoY); new Takeda pan-portfolio collaboration for MRD endpoint.","Net loss $57.7M (vs $62.8M prior); Adjusted EBITDA loss $37.1M (vs $43.1M prior).","FY2023 revenue guidance reaffirmed $205M-$215M; expects OpEx below FY2022 level of $385.5M.","Consolidation of President and COO roles under Julie Rubinstein."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":37647000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295963,"accession_number":"0001193125-23-097389","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2023-04-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Adaptive Biotech COO Mark Adams terminated; duties absorbed by President Rubinstein","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Adams, COO, was informed on April 7, 2023, that his service will be terminated by May 2023.","President Julie Rubinstein will assume the Chief Operating Officer's duties.","No replacement COO has been named; organizational impact remains unclear.","Chad Robins continues as CEO; leadership transition underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316499,"accession_number":"0000950170-23-002786","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q4 revenue $55.2M (+46% YoY); guides FY2023 rev $205M-$215M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2022 revenue $185.3M (+20% YoY); MRD revenue $87.1M (+32%), Immune Medicine $98.2M (+11%).","clonoSEQ test volume Q4 up 54% to 10,526 tests; full year up 51% to 36,871 tests.","Net loss Q4 $40.2M vs $61.4M; adjusted EBITDA loss $19.6M vs $44.9M YoY.","2023 revenue guidance $205M-$215M; operating expenses expected below $385.5M.","Long-term targets: 20-30% revenue CAGR, positive adjusted EBITDA in 2025, cash flow breakeven in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":185308000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334768,"accession_number":"0000950170-22-021886","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q3 revenue $47.8M (+21% YoY); narrows FY2022 revenue guidance to $185-190M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 revenue $47.8M vs $39.5M in Q3 2021 (+21%); clonoSEQ test volume up 52% YoY.","Immune Medicine revenue $27.9M (+18% YoY); MRD revenue $20.0M (+26% YoY).","Net loss improved to $45.3M from $56.0M; adjusted EBITDA loss $25.9M vs $41.1M.","FY2022 revenue guidance narrowed to $185-190M from $185-195M; opex now expected below $400M.","Signed $250M non-dilutive royalty financing with OrbiMed; Epic partnership for clonoSEQ EMR integration."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":130110000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352188,"accession_number":"0001564590-22-031433","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Adaptive Biotechnologies secures up to $250M non-dilutive royalty financing from OrbiMed","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $125M tranche at closing; Adaptive may draw up to $75M more (by Sept 2025) and $50M for M&A (by Sept 2025).","OrbiMed receives 5% of GAAP revenue (8% if second tranche drawn; 10% if all three drawn).","Return cap: 165% of invested capital, increasing to 175% if full repayment not made by Sept 2032.","Adaptive can repurchase revenue interests via call option; OrbiMed has put option on change of control, etc.","Cash and marketable securities were >$450M at Q2 2022; financing extends runway for growth initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352187,"accession_number":"0001564590-22-027769","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotech Q2 revenue $43.7M (+13% YoY); MRD up 38%, net loss widens","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $43.7M (+13% YoY); MRD revenue $21.3M (+38%) on 53% test volume growth; Immune Medicine $22.4M (-3%).","Net loss $52.1M vs $49.3M in Q2 2021; operating expenses $96.2M (+9% YoY).","Updated FY2022 opex guidance to $410-415M (from $425-435M); revenue reaffirmed at $185-195M.","Expanded Medicare coverage of clonoSEQ for MRD assessment in DLBCL; signed pan-portfolio agreement with major partner."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":82280000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369700,"accession_number":"0001564590-22-023130","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Adaptive Biotech shareholders elect three Class III directors, approve advisory compensation, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Chad Robins, Kevin Conroy, Michael Pellini elected as Class III directors to 2025 term.","Advisory vote on 2021 NEO compensation approved: 72.7M for, 44.5M against, 298k abstentions.","Ernst & Young ratified as independent auditor for FY2022: 129.8M for, 55k against, 71k abstentions.","All proposals passed at June 10, 2022 annual meeting; no broker non-votes for auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369699,"accession_number":"0001564590-22-017852","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q1 revenue $38.6M (+0.5% YoY); net loss widens to $62.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["clonoSEQ test volume grew 45% YoY and 12% QoQ; MRD regulatory milestone revenue of $3.0M from partner drug approval.","T-Detect Lyme sensitivity 54% vs SOC 30% at 99% specificity; launch planned for 2022 Lyme season.","Entered T-MAP collaboration with Janssen for RSV vaccine program; appointed Tycho Peterson as CFO.","Revenue guidance for FY2022 reaffirmed at $185-195M; cash and securities $500.7M as of March 31."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":38620000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388831,"accession_number":"0001564590-22-011827","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2022-03-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Chief Medical Officer Lance Baldo resigns effective March 25, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lance Baldo resigned as Chief Medical Officer to pursue a new opportunity.","Resignation effective March 25, 2022; no replacement named yet.","Baldo stated no disagreement with the company, management, or board.","Event reported under Item 8.01 as an other-event disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388830,"accession_number":"0001564590-22-009876","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2022-03-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Adaptive Biotechnologies appoints Tycho Peterson as CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Tycho Peterson as CFO effective on or before June 4, 2022; will serve as principal financial officer.","Annual salary of $425,000, plus annual incentive opportunity of 50% of salary, prorated for 2022.","Equity grants: 374,688 RSUs (4-yr vest) and 597,157 stock options (4-yr vest).","Previously Managing Director at J.P. Morgan; holds MBA from Oxford and BA from Cornell."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388829,"accession_number":"0001564590-22-005219","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2022-02-15T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q4 revenue +26% to $37.9M; CFO Chad Cohen resigns, interim CFO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $37.9M (+26% YoY); net loss $61.4M (vs $44.6M). Full year revenue $154.3M (+57%); net loss $207.3M.","Sequencing revenue Q4 $23.1M (+81% YoY); clonoSEQ clinical tests Q4 6,356 (+41%), full year 22,516 (+48%).","Development revenue Q4 $14.9M (-15% YoY); cash, equivalents and marketable securities $570.2M at Dec 31, 2021.","CFO Chad Cohen resigned effective Feb 15, 2022; Kyle Piskel appointed interim CFO.","Genentech selected TCR candidate targeting shared cancer neoantigen; T-Detect COVID EUA with over 30,000 tests ordered."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":154344000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388828,"accession_number":"0001564590-22-000785","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies guides FY2021 revenue $153M-$154M (+56% YoY); CFO Cohen to resign","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 preliminary revenue $153M-$154M, up ~56% from $98.4M in 2020.","CFO Chad Cohen resigns effective ~Feb 15, 2022 after 10-K filing; no disagreement.","Principal Accounting Officer Kyle Piskel to serve as interim CFO; permanent search initiated.","Preliminary results subject to change; full results expected around Feb 15, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":154344000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406773,"accession_number":"0001564590-21-053963","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q3 revenue up 50% to $39.5M, net loss widens; appoints new principal accounting officer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2021 revenue $39.5M (+50% YoY); sequencing revenue $22.1M (+96%), development revenue $17.4M (+16%).","Net loss $56.0M vs $36.7M in Q3 2020; adjusted EBITDA loss $41.1M vs $28.4M.","Full-year 2021 revenue guidance reaffirmed at $148-155M, ~54% growth at midpoint.","clonoSEQ sequencing volume grew 47% YoY; launched enhanced assay for CLL including IGHV mutation status.","Kyle Piskel appointed principal accounting officer; Chad Cohen remains CFO and principal financial officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":116414000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425781,"accession_number":"0001564590-21-040826","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q2 revenue $38.5M, +83% YoY; raises FY2021 guidance to $148M-$155M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $38.5M (+83% YoY); sequencing revenue $18.6M (+132%), development revenue $20.0M (+53%).","Net loss $49.3M vs $33.5M YoY; adjusted EBITDA loss $35.6M vs $28.5M.","FY2021 revenue guidance raised to $148M-$155M (prior $145M-$155M).","clonoSEQ volume +75% YoY; signed agreements with Vaccibody and Moderna for T-cell data and COVID vaccine T-cell response measurement.","Cash and marketable securities $689.5M as of June 30, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":76947000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}